A cytochrome P450 3A (CYP3A) inhibitor that can be used to enhance the pharmacokinetic profile of certain anti-HIV-1 agents. Upon administration, cobicistat inhibits the liver enzyme CYP3A4 and limits the breakdown of co-administered agents that are metabolized by CYP3A4, and increases the... more
A cytochrome P450 3A (CYP3A) inhibitor that can be used to enhance the pharmacokinetic profile of certain anti-HIV-1 agents. Upon administration, cobicistat inhibits the liver enzyme CYP3A4 and limits the breakdown of co-administered agents that are metabolized by CYP3A4, and increases the concentration, systemic exposure and efficacy of the co-administered agent. NCI Thesaurus
Evotaz; Genvoya; Prezcobix; Stribild; Symtuza; Tybost
Cytochrome P450 3A Inhibitors
Tybost (cobicista) dosing, indications, interactions, adverse effects, and more.
Viewing results 1 - 10 of 521,000 (0.23 seconds)
Jan 15, 2022 ... Cobicistat is in a class of medications called pharmacokinetic boosters. It works by increasing the amount of atazanavir or darunavir in the ...
Cobicistat (brand name: Tybost) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for use in adults and children along with the ...
Cobicistat is a CYP3A inhibitor used to increase the systemic exposure of atazanavir or darunavir in combination with other antiretroviral agents in the ...
USES: This drug is used to increase ("boost") the levels of certain HIV protease inhibitors (atazanavir and darunavir). This helps them work better to help ...
Cobicistat (Tybost™) is a mechanism-based inhibitor of cytochrome P450 (CYP) 3A enzymes that is indicated in the EU as a pharmacokinetic enhancer (i.e. ...
Nov 29, 2016 ... We evaluated the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (Stribild®) prescribed as one ...
Cobicistat is a strong mechanism-based CYP3A inhibitor and is a CYP3A substrate. Increased plasma concentrations of medicinal products that are metabolised by ...
6.1Drug Indication · Cobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in ...
Cobicistat has been studied as a booster for elvitegravir, a second-generation integrase inhibitor, and protease inhibitors. Based on successful clinical trials ...
EMEA/H/C/002572. Active substance. cobicistat. International non-proprietary name (INN) or common name. cobicistat. Therapeutic area (MeSH). HIV Infections.